ENOV ENOVIS CORPORATION

Enovis to Host First Quarter 2025 Results Conference Call on May 8th

Enovis to Host First Quarter 2025 Results Conference Call on May 8th

Wilimington, DE, April 17, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its first quarter 2025 financial results on Thursday, May 8th, 2025 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call, as well as a webcast, can be accessed from the "Investors" section of Enovis' website at .

Conference Call/Webcast Information

Investors can access the live webcast via a link on the Enovis website. For those planning to participate on the call, please dial (833) 335-0887 and use the Access Code: 482081. Participants may also preregister at . A replay of the call will also be available on the Enovis website later that day.

About Enovis

Enovis Corporation (NYSE: ENOV) is an innovation-driven medical technology growth company dedicated to developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. Powered by a culture of continuous improvement, global talent and innovation, the Company’s extensive range of products, services and integrated technologies fuels active lifestyles in orthopedics and beyond. The Company’s shares of common stock are listed in the United States on the New York Stock Exchange under the symbol ENOV. For more information about Enovis, please visit .

Availability of Information on the Enovis Website

Investors and others should note that Enovis routinely announces material information to investors and the marketplace using SEC filings, press releases, public conference calls, webcasts and the Enovis Investor Relations website. While not all of the information that the Company posts to the Enovis Investor Relations website is of a material nature, some information could be deemed to be material. Accordingly, the Company encourages investors, the media and others interested in Enovis to review the information that it shares on ir.enovis.com.

Contact:

Kyle Rose

Vice President, Investor Relations

Enovis Corporation



EN
17/04/2025

Underlying

ENOVENOVIS CORPORATION

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ENOVIS CORPORATION

 PRESS RELEASE
Free
ENOV ENOVIS CORPORAT...

Enovis to Host First Quarter 2025 Results Conference Call on May 8th

Enovis to Host First Quarter 2025 Results Conference Call on May 8th Wilimington, DE, April 17, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its first quarter 2025 financial results on Thursday, May 8th, 2025 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call, as well as a webcast, can be accessed from the "Investors" section of Enovis' website at . Conference Call/We...

April 17, 2025 1 EN
 PRESS RELEASE
Free
ENOV ENOVIS CORPORAT...

Enovis Announces Appointment of Damien McDonald as Chief Executive Off...

Enovis Announces Appointment of Damien McDonald as Chief Executive Officer Damien McDonald appointed CEO, effective as of May 12, 2025Company reiterates guidance for first quarter revenues and aEBITDA WIlmington. DE, April 02, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “The Company”) (NYSE: ENOV), a leader in medical technology innovation, today announced the appointment of Damien McDonald as Chief Executive Officer, effective May 12, 2025. Mr. McDonald will also join the Enovis Board of Directors following the conclusion of the Company’s 2025 Annual Meeting of Stockholde...

April 2, 2025 1 EN
 PRESS RELEASE
Free
ENOV ENOVIS CORPORAT...

Enovis™ to Exhibit Extensive Range of Foot & Ankle Solutions at ACFAS...

Enovis™ to Exhibit Extensive Range of Foot & Ankle Solutions at ACFAS 2025 Alongside an evidence-based portfolio, Enovis will showcase how it’s “Redefining Every Step” with confidence-building education and a partnership that goes beyond the product; attendees invited to exclusive events. WILMINGTON, DE, March 25, 2025 (GLOBE NEWSWIRE) -- Enovis™ (NYSE: ENOV), a global medical technology innovator, will feature its expanding portfolio of foot and ankle solutions at this year’s American College of Foot & Ankle Surgeons (ACFAS) Annual Scientific Conference in Phoenix, Ariz., taking plac...

March 25, 2025 1 EN
 PRESS RELEASE
Free
ENOV ENOVIS CORPORAT...

Enovis to Participate in Upcoming Investor Conferences

Enovis to Participate in Upcoming Investor Conferences Wilmington, DE, March 05, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences: Canaccord Genuity Musculoskeletal Conference: Ben Berry, Chief Financial Officer, and Louie Vogt, Group President - Recon, will participate in a fireside chat on Monday, March 10th at 10:00 a.m. Pacific Time.37th Annual Roth Conference: Louie Vogt, Group President - Recon, will participate in a fi...

March 5, 2025 1 EN
 PRESS RELEASE
Free
ENOV ENOVIS CORPORAT...

Enovis Announces Fourth Quarter and Full Year 2024 Results

Enovis Announces Fourth Quarter and Full Year 2024 Results Continued commercial momentum with fourth-quarter sales growth of 23% on a reported basis and strong adjusted EBITDA margin expansion Fourth-quarter Reconstructive sales grew 59% year-over-year on a reported basis and 10% on a Comparable Sales basis Exceeded year one commercial and integration plans for Lima Wilmington, DE, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the fourth ...

February 26, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch